Navigation Links
Cancers' sweet tooth may be weakness
Date:11/18/2009

The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.

Scientists who study cancer have known for decades that cancer cells tend to consume more glucose, or blood sugar, than healthy cells. This tendency is known as the "Warburg effect," honoring discoverer Otto Warburg, a German biochemist who won the 1931 Nobel Prize in Medicine. Now a Winship-led team has identified a way to possibly exploit cancer cells' taste for glucose.

The results were published this week in the journal Science Signaling.

Normally cells have two modes of burning glucose, comparable to sprinting and long-distance running: glycolysis, which doesn't require oxygen and doesn't consume all of the glucose molecule, and oxidative phosphorylation, which requires oxygen and is more thorough.

Cancer cells often outgrow their blood supply, leading to a lack of oxygen in a tumor, says Jing Chen, PhD, assistant professor of hematology and medical oncology at Emory University School of Medicine and Winship Cancer Institute. They also benefit from glycolysis because leftovers from the inefficient consumption of glucose can be used as building blocks for growing cells.

"Even if they have oxygen, cancer cells still prefer glycolysis," Chen says. "They depend on it to grow quickly."

Working with Chen, postdoctoral researcher Taro Hitosugi focused on the enzyme PKM2 (pyruvate kinase M2), which governs the use of glucose and controls whether cells make the switch between glycolysis and oxidative phosphorylation. PKM2 is found predominantly in fetal cells and in tumor cells.

In many types of cancer, mutations lead to over-activation of proteins called tyrosine kinases. Chen's team showed that tyrosine kinases turn off PKM2 in lung, breast, prostate and blood cancers. Introducing a form of PKM2 that is not sensitive to tyrosine kinases into cancer cells forces them to grow slower and be more dependent on oxygen, they found.

Because the active form of PKM2 consists of four protein molecules stuck together, having a tyrosine kinase flip the "off" switch on one molecule can dampen the activity for the others.

"People knew that tyrosine kinases might modify PKM2 for decades but they didn't think it mattered," Chen says. "We showed that such a modification is important and you even don't need that much modification of PKM2 to make a difference in the cells' metabolism."

PKM2 could be a good drug target, because both inhibiting it or activating it can slow down cancer cell growth. Biotechnology companies are already searching for ways to do so, Chen says.


'/>"/>

Contact: Vince Dollard
vdollar@emory.edu
404-778-4580
Emory University
Source:Eurekalert

Related biology news :

1. Loss of tumor supressor gene essential to transforming benign nerve tumors into cancers
2. New blood tests promise simple, cost-effective diagnosis of gastrointestinal cancers
3. Fox Chase researchers uncover one force behind the MYC oncogene in many cancers
4. Possible drug target found for one of the most aggressive breast cancers
5. Newly discovered epidermal growth factor receptor active in human pancreatic cancers
6. NC State researchers find soy may aid in treating canine cancers
7. Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target
8. Oral rinses used for tracking HPV-positive head and neck cancers holds promise for cancer screening
9. On the trail of a targeted therapy for blood cancers
10. H. Pylori bacteria may help prevent some esophageal cancers
11. Researchers identify cancer-causing gene in many colon cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... BOULDER, Colo. , Jan. 5, 2017 /PRNewswire/ ... join the "Digital Life Alliance" established by iCarbonX, ... in 2015 to build a "Global Digital Health ... based on a combination of individual,s biological, behavioral ... Under the agreement between the companies, SomaLogic will ...
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
(Date:1/3/2017)... -- Onitor, provider of digital health technology for consumers, ... biometric data-driven program designed to aid weight loss for ... Consumer Electronics Show (CES) in Las Vegas ... World Health Organization (WHO), have identified lifestyle risks that ... overweight or obese. WHO also states that more people ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... -- The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), ... - Global Forecast to 2022", published by MarketsandMarkets, the global market is estimated ... USD 1,399.6 Million by 2022, at a CAGR of 6.96% from 2016. ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Ovation Fertility™ ... and reliable preimplantation genetic screening (PGS). , “Our genetics and IVF teams are ... Fertility Genetics Scientific Director Amy Jones, M.S., ELD (ABB) , who has ...
(Date:1/11/2017)...  Brian Mehling, M.D., world-renowned stem cell researcher, board-certified ... (BHI), will be attending the 47th Annual World Economic ... January 17-20, 2017. This will be Dr. Mehling,s fifth ... of this year,s forum is Responsive and Responsible Leadership; ... strategies for fostering greater social inclusion and human development. ...
(Date:1/11/2017)... ... January 11, 2017 , ... Microbial genomics ... microbiome studies. Its most recent microbiome impact grant award has been made to ... effect of long-term use of oral antibiotics, prescribed for skin conditions, on the ...
Breaking Biology Technology: